Sarepta Therapeutics Inc (NAS:SRPT)
$ 121.5 -1.87 (-1.52%) Market Cap: 11.61 Bil Enterprise Value: 11.98 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 86/100

Sarepta Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 11, 2023 / 12:40PM GMT
Release Date Price: $118.4 (-1.26%)
Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst

All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the biotech analyst here. And it's my pleasure to introduce the team from Sarepta Therapeutics including Doug Ingram, CEO; and Ian Estepan, CFO. Just a reminder, the format for today is a fireside chat. But before we get started, I just need to read a quick disclaimer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representatives. And with that, maybe, Doug, I can just turn it over to you to give us a sort of quick background.

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Sure. I'll be -- I'll try my best to be brief. I know these are -- all of these are going to come up in Q&A. Look

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot